NeuroTherapia is an anti-aging biotech company focused on developing treatments for neuroinflammatory conditions, with a particular emphasis on neurodegenerative diseases like Alzheimer’s. Their mission is to create therapies that address the underlying causes of these conditions, aiming to preserve cognitive function and potentially slow the aging process.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
NeuroTherapia’s approach centers around targeting neuroinflammation, a critical factor in neurodegenerative diseases and cognitive decline associated with aging.
NTRX-07: The Lead Candidate
Their primary therapeutic candidate, NTRX-07, is designed to modulate immune responses within the central nervous system (CNS), specifically by interacting with microglia cells, which are pivotal in managing inflammation in the brain.
NTRX-07 is a small-molecule drug that acts on the cannabinoid receptor CB2, a crucial component in the regulation of the immune system within the CNS. Microglia cells, which are the primary immune cells of the CNS, become activated in response to injury or disease, leading to inflammation. In neurodegenerative conditions such as Alzheimer’s disease, this inflammation can become chronic, contributing to further neuronal damage and cognitive decline. By targeting CB2 receptors on microglia, NTRX-07 aims to reduce this harmful inflammation, thereby slowing the progression of neurodegenerative diseases.
The following image from NeuroTherapia’s official website illustrates NTRX-07’s mechanism of action:
NeuroTherapia has successfully conducted a Phase 1b study of NTRX-07 demonstrated promising results, particularly in terms of safety and tolerability in patients with Alzheimer’s disease. The study found that NTRX-07 was well-tolerated at the tested doses, with no serious adverse events reported. Additionally, there were indications of reduced neuroinflammation, as evidenced by biomarker analysis, and some patients showed stabilization or improvement in cognitive function. These findings support further exploration of NTRX-07 in subsequent trials to evaluate its efficacy in treating neurodegenerative diseases.
Pipeline Expansion
Beyond NTRX-07, NeuroTherapia is actively investigating additional compounds that could complement their current approach or offer alternative mechanisms to combat neuroinflammation and aging. Their research extends into understanding how different inflammatory pathways contribute to aging and disease, hopefully allowing them to identify new targets for therapeutic intervention.
The Company
NeuroTherapia, Inc. is a biotech company based in Cleveland, Ohio, founded in 2015 as a spin-off from the Cleveland Clinic. The company was co-founded by Dr. Joseph Foss, who also serves as the CMO, and Dr. Mohamed Naguib, a scientific advisor and co-discoverer of the company’s lead drug candidate, NTRX-07.
NeuroTherapia has successfully raised funding to support its research and development efforts. The company secured $8.8 million in a Series A financing round in 2020, led by the Brain Trust Accelerator Fund II, and included investments from the Cleveland Clinic Foundation, Dolby Family Ventures, and the Alzheimer’s Drug Discovery Foundation. In 2024, they further secured $12.3 million in a Series B financing round, with continued support from these key investors.
The most recent round of funding is to further the clinical development of the lead candidate NTRX-07 and advance it through a Phase 2a trial. At this point no specific timelines for the initiation of this next clinical trial phase have been publicly detailed. This next phase will be crucial in further evaluating the efficacy of NTRX-07 in a larger patient population, particularly in terms of its impact on neuroinflammation and cognitive function in Alzheimer’s disease.
If you want to learn more about NeuroTherapia you can view their official website through this link.
Read about more anti-aging companies on this website through this link.
